Background/Aims: Islet metabolic disorder and inflammation contribute to the pathogenesis and progression of type 2 diabetes mellitus (T2DM). Irisin is a recently identified adipomyokine with protective effects on metabolic homeostasis and inflammation-suppressing effects in hepatic and vascular cells. The present study examined the effects of irisin on lipid metabolism and inflammation in β cells under glucolipotoxic conditions. Methods: Rat INS-1E β cells and islets isolated from C57BL/6 mice were incubated in glucolipotoxic conditions with or without irisin. Intracellular lipid contents and lipogenic gene expression were determined by enzymatic colorimetric assays and real-time PCR, respectively. Inflammatory status was evidenced by Western blot analysis for the phosphorylation of nuclear factor-κB (NF-κB) p65 and real-time PCR analysis for the expression of pro-inflammatory genes. Results: Irisin reversed glucolipotoxicity-induced intracellular non-esterified fatty acid (NEFA) and triglyceride accumulation, suppressed associated elevations in lipogenic gene expression, and phosphorylated acetyl-CoA-carboxylase (ACC) in INS-1E cells. These demonstrated effects were dependent on irisin-activated adenosine monophosphate-activated protein kinase (AMPK). Meanwhile, AMPK signaling mediated the protective effects of irisin on INS-1E cell insulin secretory ability and survival as well. Additionally, irisin inhibited phosphorylation of NF-κB p65 while decreasing the expression of pro-inflammatory genes in INS-1E cells under glucolipotoxic conditions. Moreover, irisin also improved insulin secretion, inhibited apoptosis, and restored β-cell function-related gene expression in isolated mouse islets under glucolipotoxic conditions. Conclusion: Irisin attenuated excessive lipogenesis in INS-1E cells under glucolipotoxic state through activation of AMPK. Irisin also suppressed overnutrition-induced inflammation in INS-1E cells. Our findings implicate irisin as a promising therapeutic target for the treatment of islet lipid metabolic disorder and islet inflammation in T2DM.

In obese subjects, hyperglycemia and hyperlipidemia contribute to the development and progression of type 2 diabetes mellitus (T2DM) through mechanisms that involve the phenomenon, namely islet β-cell failure, a condition characterized by islet β-cell dysfunction and loss of β-cell mass [1]. Accordingly, chronic exposure to high levels of glucose and palmitic acid (PA) has been shown to impair β-cell insulin secretion and promote β-cell apoptosis in in vitro and ex vivo studies [2, 3]. Overnutrition-related glucolipotoxicity perturbs normal lipid metabolism in β cells and islets by promoting lipogenesis and subsequent lipid deposition [2]. Meanwhile, glucolipotoxicity triggers intra-islet inflammation, especially in β cells, as well [4, 5]. The abnormalities in lipid metabolism and inflammation under glucolipotoxic conditions are thought to be the key players of β-cell failure and pathogenesis of T2DM.

Fundamentally, T2DM is a disorder of metabolism characterized by insulin resistance in peripheral tissues (primarily adipose, hepatic and skeletal muscle tissues) and hyperglycemia due to insufficient insulin secretion. Exercise-induced secretion of small protein molecules, including myokines, can have beneficial effects on metabolic syndromes. Of particular interest in this context is irisin, a newly identified adipomyokine derived from fibronectin type III domain containing 5 (FNDC5), which has gained attention for its potential in the prevention and treatment of obesity and T2DM [6, 7]. In this regard, the circulating levels of irisin were found to be altered in obese individuals and diabetic patients [8]; these levels were considered to be one biomarker for the prediction of the development of diabetes and mortality risk of cardiovascular diseases [9, 10]. We and others have demonstrated that, in an overnutrition state, irisin can restore metabolic homeostasis, thereby alleviating insulin resistance and protecting cell function as well as survival in hepatic tissues [11-13]. For instance, irisin attenuated PA-induced excessive lipid accumulation in hepatocytes [13], while deficiency of FNDC5 exacerbated hepatic lipogenesis and lipid accumulation in obese mice [11].

Activation of adenosine monophosphate-activated protein kinase (AMPK) is associated, at least partially, with the protective effects of irisin on lipid metabolism via regulation of the expression and activity of lipogenic factors, such as acetyl-CoA-carboxylase (ACC) and fatty acid synthase (FAS) [12, 13]. AMPK is a highly evolutionarily conserved cellular energy status sensor that transmits metabolic stress signals and restores metabolic homeostasis by integrating physiological signals [14]. Its activation is facilitated by phosphorylation at its threonine 172 residue [15]. As a master metabolic regulator, activated AMPK promotes energy production via glycolysis while repressing ATP-consuming processes, such as fatty acid and triglyceride (TG) synthesis [14, 16, 17]. For instance, AMPK activation can downregulate fatty acid synthesis by phosphorylating ACC in adipose and hepatic tissues [12, 18]. In β cells, AMPK activation is speculated to limit lipid accumulation under glucolipotoxic condition [3]. Despite these findings, it remains unknown whether irisin can restore metabolic homeostasis via AMPK signaling in β cells under T2DM-like conditions.

Irisin has been reported to alleviate syndromes in T2DM and non-diabetic obesity by inhibiting inflammation in hepatic and vascular as well as adipose tissues [13, 19, 20]. For example, irisin attenuated PA-induced expression of pro-inflammatory factors, including cyclooxygenase-2 (COX2), in hepatocytes [13] and alleviated T2DM-related vascular dysfunction through repression of nuclear factor-κB (NF-κB) p65 phosphorylation in endothelial cells [19]. Irisin has also been shown to exhibit anti-inflammatory actions in macrophages via inhibiting activation of NF-κB p65 and release of cytokines, including chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 1 (CXCL1) [21]. It is well established that β-cell inflammation under hyperglycemic and hyperlipidemic milieu is attributed to the pathogenesis and development of T2DM [4, 5].

Regarding the regulatory actions on β cells, it has been reported that irisin administration attenuates β-cell apoptosis and restores β-cell function under glucotoxic condition [22]. In addition, a recent study has shown that irisin suppresses apoptosis in β cells and islets under lipotoxic condition via modulation of protein kinase B/B-cell lymphoma 2 (BCL2) signaling pathway [23]. However, it has yet to be determined whether irisin can alleviate lipid metabolic disorder and pro-inflammatory actions in β cells under T2DM-like conditions. Therefore, the present study aimed to investigate the effects of irisin on hyperlipogenesis in β cells under glucolipotoxic conditions and whether such effects were mediated by AMPK signaling. Meanwhile, the potential involvement of AMPK in the protective effects of irisin on β-cell insulin secretion and survival was assessed as well. Additionally, we examined the regulatory action of irisin on β-cell inflammation under glucolipotoxic conditions.

Cell and islet treatments

Rat INS-1E β cells were cultured in RPMI 1640 containing glucose (11.1 mM) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 50 μM 2-mercaptoethanol (all from Life Technologies, Carlsbad, CA). Intact pancreatic islets isolated from 8-wk-old male C57BL/6 mice following intra-ductal injection of collagenase P (Roche, Kaiseraugst, Switzerland) were cultured in 5.6 mM glucose containing RPMI 1640 medium supplemented with 10% (v/v) FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells and islets were maintained at 37 °C in a humidified atmosphere containing 5% CO2.

To induce glucolipotoxicity, INS-1E cells and isolated mouse islets were exposed to a PA-high glucose (PAHG) condition consisting of 0.5 mM PA and 28 mM glucose (both from Sigma-Aldrich, St. Louis, MO). To determine the effects of irisin on phosphorylation of AMPKα and ACC, cells were incubated with 1 µg/ ml recombinant irisin (University of Hong Kong, China) for 5, 15, 30, 60, or 90 min, with or without 20-min pretreatment of 5 µM compound C (Sigma-Aldrich), an AMPK inhibitor. For other assessments, cells and islets were treated with recombinant irisin for 48 h in the presence or absence of compound C.

Gene expression analysis

Total RNA extracted from INS-1E cells or isolated mouse islets with TRIzol reagent (Takara Bio., Shiga, Japan) was subjected to reverse transcription with a PrimeScript RT Master Mix kit (Takara Bio.), according to the manufacturer’s instructions. Relative gene expression levels were quantified by real-time polymerase chain reaction (PCR) using Power SYBR Green PCR Master Mix (Applied Biosystems Life Technologies, UK). The primers used were listed in Table 1. Transcript levels were calculated by the 2-ΔΔCT method [24] and normalized to β-actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Table 1.

Sequences of primers used in real-time PCR experiments

Sequences of primers used in real-time PCR experiments
Sequences of primers used in real-time PCR experiments

Western blot analysis

Total protein per standardized number of cells was extracted with CytoBuster protein extraction reagent (Novagen, Darmstadt, Germany), fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and then transferred to polyvinylidene difluoride membranes (Millipore Corp., Billerica, MA). After blocking, membranes were probed with primary antibodies targetting the following proteins: AMPKα, phosphorylated (p)-AMPKα (Thr172), acetyl-CoA-carboxylase (ACC), p-ACC (Ser79), NF-κB p65, and p-NF-κB p65 (Ser536) (Cell Signaling, Danvers, MA). After washing with phosphate buffered saline with 0.1% Tween 20, the membranes were probed with corresponding horseradish peroxidase-conjugated secondary antibodies (Cell Signaling). Labeled protein bands were revealed with a chemiluminescence system (GE Healthcare, Piscataway, NJ, USA), exposed to Fuji medical film (FUJIFILM Corp., Tokyo, Japan), and quantitated with Image J software (NIH, USA).

Measurement of lipid constituents

Intracellular TG and non-esterified fatty acid (NEFA) contents in INS-1E cell lysates were measured by specific enzymatic colorimetric kits (Wako Pure Chemicals, Osaka, Japan), according to the manufacturer’s instructions, and normalized to cellular protein concentration.

Glucose stimulated insulin secretion (GSIS)

Insulin secretory ability was assessed as described previously [25]. Briefly, INS-1E cells and isolated mouse islets were allowed to equilibrate in Krebs-Ringer bicarbonate buffer (KRBB, supplemented with 0.1% NEFA-free bovine serum albumin and 10 mM HEPES) with 1.7 mM glucose for 1 h. They were then incubated in KRBB containing 1.7 mM glucose for 1 h, and in KRBB with 16.7 mM glucose for one additional hour. Subsequently, samples from KRBB solution were subjected to insulin quantification with an enzyme-linked immunosorbent assay (ELISA) kit (University of Hong Kong, China).

Cell proliferation and apoptosis assays

INS-1E cells were seeded at a density of 1 × 104 per well in 96-well microplates and cultured under experimentally indicated conditions. Cell proliferation was determined by detecting bromodeoxyuridine (BrdU) incorporation. After cells were incubated with BrdU for 2 h, DNA synthesis was assessed with a BrdU cell proliferation ELISA kit (Roch Applied Science, Basel, Switzerland) in accordance with the manufacturer’s instructions. Cell apoptosis was assessed with a cell death detection ELISA plus kit (Roche Applied Science) according to the manufacturer’s instructions.

Statistical analysis

Data are expressed as means ± standard errors of means (SEMs). Comparisons between different groups were analyzed with one-way analyses of variance (ANOVAs) followed by Tukey’s post hoc test. In all cases, p < 0.05 was considered statistically significant.

Irisin reverses glucolipotoxicity-induced lipid hyperaccumulation in INS-1E cells

A 48-h treatment with PAHG condition led to dramatic accumulation of intracellular NEFA and TG molecules within INS-1E cells, in relation to the controls (Fig. 1A). However, co-treatment with irisin (1 µg/ml) repressed these adverse effects of PAHG (Fig. 1A), as well as reduced the upregulated mRNA expression of the key lipogenesis-related enzymes, i.e. ACC and FAS, in relation to the respective controls (Fig. 1B).

Fig. 1.

Irisin alleviated glucolipotoxicity induced lipogenesis. Intracellular levels of NEFA and TG contents (A), and expression levels of ACC and FAS mRNAs (B) in INS-1E cells exposed to PAHG condition (500 µM palmitic acid and 28 mM glucose) for 48 h with or without irisin treatment (1 µg/ml). ***p< 0.001 vs control (Ctrl); #p< 0.05, ##p< 0.01 vs PAHG group (n = 6 per group).

Fig. 1.

Irisin alleviated glucolipotoxicity induced lipogenesis. Intracellular levels of NEFA and TG contents (A), and expression levels of ACC and FAS mRNAs (B) in INS-1E cells exposed to PAHG condition (500 µM palmitic acid and 28 mM glucose) for 48 h with or without irisin treatment (1 µg/ml). ***p< 0.001 vs control (Ctrl); #p< 0.05, ##p< 0.01 vs PAHG group (n = 6 per group).

Close modal

Irisin activates AMPK-ACC signaling in INS-1E cells

As shown in Fig. 2A, acute incubation with irisin (1 µg/ml) resulted in increased levels of p-AMPKα and p-ACC in INS-1E cells under normal condition. These stimulatory effects were detectable by 15 min and 30 min after irisin treatment, respectively, and returned to the baseline levels within 90 min (Fig. 2A). Following exposure to the glucolipotoxic condition for 48 h, an 30 min-incubation with irisin resulted in increases in p-AMPKα and p-ACC in INS-1E cells (Fig. 2B). In addition, the effect of irisin on ACC phosphorylation was repressed by the AMPK inhibitor, compound C (5 µM), suggestive of its dependence on activation of AMPKα (Fig. 2B).

Fig. 2.

Irisin stimulated phosphorylation of AMPKα and ACC in INS-1E cells under normal and glucolipotoxic conditions. (A) Phosphorylated and total forms of AMPKα and ACC in INS-1E cells treated with irisin (1 µg/ml) for the indicated periods of time. *p< 0.05, **p< 0.01 vs 0 min. (B) Phosphorylated and total forms of AMPKα and ACC in INS-1E cells after 48-h incubation in PAHG medium, with or without 20-min pretreatment with compound C (5 µM) prior to 30-min irisin treatment (1 µg/ml). *p< 0.05 vs PAHG; #p< 0.05 vs PAHG+irisin (n = 3 per group).

Fig. 2.

Irisin stimulated phosphorylation of AMPKα and ACC in INS-1E cells under normal and glucolipotoxic conditions. (A) Phosphorylated and total forms of AMPKα and ACC in INS-1E cells treated with irisin (1 µg/ml) for the indicated periods of time. *p< 0.05, **p< 0.01 vs 0 min. (B) Phosphorylated and total forms of AMPKα and ACC in INS-1E cells after 48-h incubation in PAHG medium, with or without 20-min pretreatment with compound C (5 µM) prior to 30-min irisin treatment (1 µg/ml). *p< 0.05 vs PAHG; #p< 0.05 vs PAHG+irisin (n = 3 per group).

Close modal

Irisin represses lipid hyperaccumulation and expression of lipogenic genes in INS-1E cells under glucolipotoxic conditions in an AMPK-dependent manner

As shown in Fig. 3A, co-treatment with compound C resulted in a significant attenuation of the inhibitory effects of irisin on accelerated intercellular NEFA and TG deposition within INS-1E cells under glucolipotoxic conditions. Consistently, compound C-induced alterations in NEFA and TG contents were associated with parallel changes in ACC and FAS expression; in fact, compound C diminished the repressive effects of irisin on ACC and FAS transcription in INS-1E cells under glucolipotoxic conditions as well (Fig. 3B).

Fig. 3.

Irisin inhibited lipogenesis in INS-1E cells under glucolipotoxic conditions via a mechanism that requires AMPK activation. Intracellular levels of NEFA and TG contents (A), and mRNA expression levels of ACC and FAS (B) in INS-1E cells exposed to PAHG medium for 48 h with or without irisin (1 µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG; §p< 0.05, §§p< 0.01 vs PAHG+irisin group (n = 6 per group).

Fig. 3.

Irisin inhibited lipogenesis in INS-1E cells under glucolipotoxic conditions via a mechanism that requires AMPK activation. Intracellular levels of NEFA and TG contents (A), and mRNA expression levels of ACC and FAS (B) in INS-1E cells exposed to PAHG medium for 48 h with or without irisin (1 µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG; §p< 0.05, §§p< 0.01 vs PAHG+irisin group (n = 6 per group).

Close modal

Irisin restores GSIS of INS-1E cells under glucolipotoxic conditions via AMPK

The glucolipotoxic treatment reduced the insulin secretory response of INS-1E cells to 16.7 mM glucose challenge (normalized to insulin secretion at 1.7 mM glucose) by about 50%, and this reduction was partially reversed by co-treatment with irisin. Conversely, co-incubation with the AMPK inhibitor compound C attenuated this protective effect of irisin on insulin secretion (Fig. 4A). In addition, the levels of transcripts encoding for glucose transporter 2 (GLUT2) and glucokinase (GLK), the two key enzymes that facilitate GSIS, were altered in the same patterns. Irisin partially reversed the decreased mRNA expression of GLUT2 and GLK under glucolipotoxic condition, while compound C co-treatment repressed those protective effects (Fig. 4B).

Fig. 4.

Irisin protected GSIS of INS-1E cells under glucolipotoxic conditions in an AMPK-dependent manner. GSIS in response to 16.7 mM glucose in reference to 1.7 mM glucose (A), and mRNA expression of GLUT2 and GLK (B) in INS-1E cells exposed to PAHG condition for 48 h with or without irisin (1 µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05 vs PAHG; §p< 0.05 vs PAHG+irisin group (n = 6 per group).

Fig. 4.

Irisin protected GSIS of INS-1E cells under glucolipotoxic conditions in an AMPK-dependent manner. GSIS in response to 16.7 mM glucose in reference to 1.7 mM glucose (A), and mRNA expression of GLUT2 and GLK (B) in INS-1E cells exposed to PAHG condition for 48 h with or without irisin (1 µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05 vs PAHG; §p< 0.05 vs PAHG+irisin group (n = 6 per group).

Close modal

Irisin improves INS-1E cell survival via AMPK under glucolipotoxic conditions

As shown in Fig. 5A, cell proliferation of INS-1E cells was impaired while cell apoptosis was increased dramatically upon the glucolipotoxic exposure, and these glucolipotoxicity-induced effects were attenuated by co-treatment with irisin. On the other hand, AMPK inhibition with compound C diminished the protective effects of irisin on INS-1E cell proliferation and apoptosis under the glucolipotoxic conditions (Fig. 5A). In corroboration with these findings, compound C inhibited irisin-mediated regulation of the mRNA expression of pancreas/duodenum homeobox protein 1 (Pdx1) and Bcl2, two master regulatory genes for β cell proliferation and apoptosis, in INS-1E cells chronically exposed to high levels of PA and glucose (Fig. 5B).

Fig. 5.

Irisin countered glucolipotoxic effects on the cell proliferation and apoptosis in INS1-E cells through AMPK activation. (A) Cell proliferation (left) and apoptosis (right), and mRNA expression of PDX1 and BCL2 (B) in INS-1E cells exposed to PAHG medium for 48 h with or without irisin (1µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01, ###p< 0.001 vs PAHG (n = 6 per group).

Fig. 5.

Irisin countered glucolipotoxic effects on the cell proliferation and apoptosis in INS1-E cells through AMPK activation. (A) Cell proliferation (left) and apoptosis (right), and mRNA expression of PDX1 and BCL2 (B) in INS-1E cells exposed to PAHG medium for 48 h with or without irisin (1µg/ml) and compound C (5 µM). ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01, ###p< 0.001 vs PAHG (n = 6 per group).

Close modal

Irisin exhibits anti-inflammatory effects in INS-1E cells under glucolipotoxic conditions

A 48-h PAHG incubation triggered pro-inflammatory responses in INS-1E cells, as indicated by elevated expression levels of mRNAs encoding COX2, CXCL1 and CCL2, as well as phosphorylation of p65 (Fig. 6). Co-treatment with irisin inhibited PAHG-induced expression of the above three pro-inflammatory factors (Fig. 6A), whilst repressing p65 phosphorylation in INS-1E cells under glucolipotoxic conditions (Fig. 6B).

Fig. 6.

Irisin attenuated glucolipotoxicity induced inflammation in INS-1E cells. (A) mRNA expression of COX2, CXCL1, and CCL2 (n = 6 per group), and (B) phosphorylated and total forms of p65 (n= 3 per group) in INS-1E cells exposed to PAHG condition for 48 h with or without irisin (1 µg/ml). *p< 0.05, ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG.

Fig. 6.

Irisin attenuated glucolipotoxicity induced inflammation in INS-1E cells. (A) mRNA expression of COX2, CXCL1, and CCL2 (n = 6 per group), and (B) phosphorylated and total forms of p65 (n= 3 per group) in INS-1E cells exposed to PAHG condition for 48 h with or without irisin (1 µg/ml). *p< 0.05, ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG.

Close modal

Irisin improves insulin secretion, attenuates apoptosis, and modulates expression of related genes in isolated mouse islets under glucolipotoxic conditions

A 48-h incubation with PAHG conditions impaired GSIS and augmented apoptosis in islets isolated from mice (Fig. 7A). In line with our observations on INS-1E cells, co-treatment with irisin (1 µg/ml) restored GSIS and reduced PAHG-induced apoptosis in isolated mouse islets (Fig. 7A). Consistently, irisin restored the expression of genes that are positively associated with GSIS (Glut2) and β-cell function (Pdx1) and negatively correlated with apoptosis (Bcl2) in mouse islets under ex vivo glucolipotoxic conditions (Fig. 7B).

Fig. 7.

Irisin protected GSIS and repressed apoptosis in isolated mouse islets under glucolipotoxic conditions. (A) GSIS in response to 16.7 mM glucose in reference to 1.7 mM glucose (left) and cell apoptosis (right), and (B) mRNA expression of GLK, PDX1, and BCL2 (B) in islets isolated from mice and exposed to PAHG for 48 h with or without irisin (1 µg/ml). *p< 0.05, ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG group (n = 6 per group).

Fig. 7.

Irisin protected GSIS and repressed apoptosis in isolated mouse islets under glucolipotoxic conditions. (A) GSIS in response to 16.7 mM glucose in reference to 1.7 mM glucose (left) and cell apoptosis (right), and (B) mRNA expression of GLK, PDX1, and BCL2 (B) in islets isolated from mice and exposed to PAHG for 48 h with or without irisin (1 µg/ml). *p< 0.05, ***p< 0.001 vs Ctrl; #p< 0.05, ##p< 0.01 vs PAHG group (n = 6 per group).

Close modal

The present study is the first to have reported the regulatory actions of irisin on β-cell lipid metabolism and inflammation under glucolipotoxic conditions that mimic T2DM. Irisin administration reversed the elevation of intracellular NEFA and TG content, repressed the induced expression of lipogenic genes and inhibited ACC activity, as well as improved the GSIS and enhanced the survival of INS-1E cells under T2DM-like state. These beneficial effects of irisin on lipogenesis, insulin release and cell survival were found to be dependent on irisin-activated AMPK. Meanwhile, irisin suppressed the phosphorylation of NF-κB p65 and expression of inflammatory genes in INS-1E cells under glucolipotoxic conditions. Fig. 8 is a schematic summary proposing irisin’s protection against glucolipotoxicity-mediated islet b-cell dysfunction, apoptosis and inflammation.

Fig. 8.

Schematic diagram summarizing the regulatory actions of irisin in lipid metabolism, cell survival, and inflammation in INS-1E cells and islets experiencing glucolipotoxicity. Irisin treatment leads to phosphorylation of AMPKα, thereby inhibiting ACC activity and repressing expression of lipogenic enzymes (ACC and FAS). Consequently, lipogenesis and the intracellular NEFA and TG accumulation are decreased, resulting in the protective effects on expression of genes related to β-cell survival (Pdx1 and Bcl2) and function (Glut2 and Glk). Ultimately, cellular proliferation and GSIS are restored, while apoptosis is inhibited. Additionally, irisin exhibits anti-inflammatory effects via attenuation of the induction of p65 phosphorylation and thus attenuation of expression of downstream pro-inflammatory factors ensues (COX2, CCL2 and CXCL1).

Fig. 8.

Schematic diagram summarizing the regulatory actions of irisin in lipid metabolism, cell survival, and inflammation in INS-1E cells and islets experiencing glucolipotoxicity. Irisin treatment leads to phosphorylation of AMPKα, thereby inhibiting ACC activity and repressing expression of lipogenic enzymes (ACC and FAS). Consequently, lipogenesis and the intracellular NEFA and TG accumulation are decreased, resulting in the protective effects on expression of genes related to β-cell survival (Pdx1 and Bcl2) and function (Glut2 and Glk). Ultimately, cellular proliferation and GSIS are restored, while apoptosis is inhibited. Additionally, irisin exhibits anti-inflammatory effects via attenuation of the induction of p65 phosphorylation and thus attenuation of expression of downstream pro-inflammatory factors ensues (COX2, CCL2 and CXCL1).

Close modal

In T2DM, hyperglycemia and hyperlipidemia contribute synergistically to ectopic lipid accumulation in β cells by promoting lipogenesis when glucose and lipid intake exceed cellular storage and oxidation capacity [2, 26, 27]. Mechanistically, lipogenesis and lipid deposition in β cells are positively associated with the activity and/or expression of ACC and FAS [28, 29]. The long-term exposure to high levels of glucose and lipid can lead to induction of ACC and FAS in β cells [2, 28, 30], while the activity of ACC can be suppressed by reversible phosphorylation [29, 31]. ACC can catalyze acetyl-CoA carboxylation to generate malonyl-CoA. Subsequently, FAS facilitates de novo biosynthesis of long-chain saturated fatty acids from malonyl-CoA; the resultant fatty acids are essential for TG synthesis via esterification [28, 32].

AMPK is a metabolic sensor and regulator that modulates glucose and lipid metabolism in diverse tissues and cells [17, 33], including β cells [27, 29]. Notably, it is the main kinase that mediates the activity-suppressing phosphorylation of ACC [29, 31]. Our present findings, showing that irisin treatment of INS-1 cells suppressed glucolipotoxicit yassociated changes in ACC and FAS expression, as well as ACC phosphorylation and hyperlipogenesis via AMPK signaling, are consistent with and extend prior reports. Specifically, these findings are in line with our previous observations that AMPK mediates the inhibitory effects of irisin on ACC and FAS, and the subsequent ectopic lipogenesis in hepatic cells under T2DM-like conditions [12]. The present findings are also consistent with previous report that irisin inhibited PA-induced ACC and FAS expression and lipid accumulation in hepatocytes [13].

Our results also implicate that AMPK signaling is involved in the protective effects of irisin on β-cell insulin secretion and survival, particularly under glucolipotoxic conditions. In this context, we found that AMPK was necessary for the beneficial effects of irisin on the expression of Glut2, Glk, Pdx1 and Bcl2, which have vital roles in GSIS and/or β-cell function and survival [34-38]. AMPK activation in β cells has been shown to restore impaired GSIS and to inhibit apoptosis in nutrient oversupply states [3, 39]. In contrast, inactivation of AMPK in β cells triggers TG deposition and attenuates insulin secretory capacity [29]. It is thus plausible to speculate that the protective effects of irisin on β-cell function and viability observed here may be due, at least partly, to lipid metabolism-altering effects.

Alterations in lipid metabolism triggered by glucolipotoxicity are instrumental in the process of β-cell dysfunction and apoptosis [2]. Glucotoxicity/lipotoxicity-induced lipid hyperaccumulation correlates with GSIS defects in β cells [2, 40]. Mechanistically, the induction in ACC contributes, at least in part, to the upregulation of TG synthesis, and consequently to impaired β-cell function in the over nutritional states [2, 29]. Meanwhile, glucolipotoxicity-induced lipogenic signaling, such as ACC, causes β-cell apoptosis as well [2, 3]. We found that AMPK mediated the effects of irisin on both lipogenic homeostasis and β-cell function/survival. Given the detrimental effects of excessive lipogenesis on β-cell function and viability, we speculate that the protective effects of irisin on β-cell insulin secretion and survival are, at least in part, secondary to irisin-AMPK signaling-mediated inhibition of lipogenesis under glucolipotoxic conditions.

In addition to demonstrating the protective effects of irisin on β-cell lipid metabolic homeostasis, the present study also showed that irisin administration can inhibit glucolipotoxicity-induced inflammatory responses in INS-1E cells. Hyperglycemia and hyperlipidemia both cause pro-inflammatory responses in macrophages, pancreatic islets, vascular tissues and other peripheral tissues, leading to T2DM pathogenesis [13, 19, 41-43]. In this regard, inhibitory effects of irisin on pro-inflammatory actions in macrophages, endothelial cells and hepatocytes can alleviate diabetic syndromes [13, 19, 21]. Consistently, our findings indicate that irisin can moderate the induction in NF-κB p65 phosphorylation under glucolipotoxic conditions. In fact, activation of NF-κB p65 is able to promote the expression of a series of pro-inflammatory factors (e.g. COX2, CCL2 and CXCL1) in diverse tissues and cells, such as β cells [44-46].

Irisin is an exercise-induced adipomyokine and circulating irisin levels are significantly elevated after both acute and chronic exercise [6, 47-49]. Moreover, it has been reported that exercise-stimulated release of irisin is independent of age or fitness level [49], although there are differences in the basal circulating irisin levels [48, 49]. Accumulating evidence have shown that irisin exhibits protective effects on glucose homeostasis in obesity and T2DM, probably via the modulation of glucose and lipid metabolism in hepatic tissue and skeletal muscle [11, 12, 50, 51]. The present study extends the previous findings via demonstrating the protective action of irisin on β-cell lipid metabolism and inflammation under type 2 diabetic condition. Our findings, if confirmed, will provide extra evidence for the beneficial action of physical exercise-induced irisin in glucose homeostasis in obesity and obesity-related T2DM.

In summary, we found that irisin countered glucolipotoxicity-induced lipid metabolic dysfunction in INS-1E cells via a mechanism that involves AMPK signaling. We also found that irisin inhibited β-cell pro-inflammatory responses to glucolipotoxicity. These findings provide scientific basis for the notion that the adipomyokine irisin has preventative and therapeutic potential for pancreatic β-cell failure due to excessive lipogenesis and inflammation triggered by hyperglycemia and hyperlipidemia in T2DM via modulation of β-cell lipid metabolism and inflammation.

This work was fully supported by the General Research Fund of The Research Grants Council of the Hong Kong Special Administrative Region, China (Ref. No.: CUHK14107415), awarded to PS Leung. INS-1E cells were a gift from Dr. Pierre Maechler, University of Geneva, Switzerland.

No conflict of interests exists.

1.
Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, and Weir GC: beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751-1758.
2.
El-Assaad W, Joly E, Barbeau A, Sladek R, Buteau J, Maestre I, Pepin E, Zhao S, Iglesias J, Roche E, and Prentki M: Glucolipotoxicity alters lipid partitioning and causes mitochondrial dysfunction, cholesterol, and ceramide deposition and reactive oxygen species production in INS832/13 ss-cells. Endocrinology 2010; 151: 3061-3073.
3.
El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, and Prentki M: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144: 4154-4163.
4.
Donath MY, Dalmas E, Sauter NS, and Boni-Schnetzler M: Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab 2013; 17: 860-872.
5.
Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake K, Tobe K, Arai H, Kadowaki T, and Nagai R: Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 2012; 15: 518-533.
6.
Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, and Spiegelman BM: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468.
7.
Leung PS: The potential of irisin as a therapeutic for diabetes. Future Med Chem 2017; 9: 529-532.
8.
Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud AA, Mousa MM, and Khalifa A: Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life 2016; 68: 544-556.
9.
Erol O, Erkal N, Ellidag HY, Isenlik BS, Aydin O, Derbent AU, and Yilmaz N: Irisin as an early marker for predicting gestational diabetes mellitus: a prospective study. J Matern-Fetal Neo M 2016; 29: 3590-3595.
10.
Shen S, Gao R, Bei Y, Li J, Zhang H, Zhou Y, Yao W, Xu D, Zhou F, Jin M, Wei S, Wang K, Xu X, Li Y, Xiao J, and Li X: Serum irisin predicts mortality risk in acute heart failure patients. Cell Physiol Biochem 2017; 42: 615-622.
11.
Liu TY, Xiong XQ, Ren XS, Zhao MX, Shi CX, Wang JJ, Zhou YB, Zhang F, Han Y, Gao XY, Chen Q, Li YH, Kang YM, and Zhu GQ: FNDC5 alleviates hepatosteatosis by restoring AMPK/mTOR-mediated autophagy, fatty acid oxidation, and oipogenesis in mice. Diabetes 2016; 65: 3262-3275.
12.
So WY, and Leung PS: Irisin ameliorates hepatic glucose/lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling. Int J Biochem Cell Biol 2016; 78: 237-247.
13.
Park MJ, Kim DI, Choi JH, Heo YR, and Park SH: New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro. Cell Signal 2015; 27: 1831-1839.
14.
Kahn BB, Alquier T, Carling D, and Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
15.
Long YC, and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116: 1776-1783.
16.
Ruderman N, and Prentki M: AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004; 3: 340-351.
17.
Cheng S, So WY, Zhang D, Cheng Q, Boucher BJ, and Leung PS: Calcitriol reduces hepatic triglyceride accumulation and glucose output through Ca2+/CaMKKb/AMPK activation under insulin-resistant conditions in type 2 diabetes mellitus. Curr Mol Med 2016; 16: 747-758.
18.
Bijland S, Mancini SJ, and Salt IP: Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013; 124: 491-507.
19.
Zhu D, Wang H, Zhang J, Zhang X, Xin C, Zhang F, Lee Y, Zhang L, Lian K, Yan W, Ma X, Liu Y, and Tao L: Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol 2015; 87: 138-147.
20.
Hou N, Du G, Han F, Zhang J, Jiao X, and Sun X: Irisin regulates heme oxygenase-1/adiponectin axis in perivascular adipose tissue and improves endothelial dysfunction in diet-induced obese mice. Cell Physiol Biochem 2017; 42: 603-614.
21.
Mazur-Bialy AI, Pochec E, and Zarawski M: Anti-inflammatory properties of irisin, mediator of physical activity, are connected with TLR4/MyD88 signaling pathway activation. Int J Mol Sci 2017; 18: 701.
22.
Liu S, Du F, Li X, Wang M, Duan R, Zhang J, Wu Y, and Zhang Q: Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic beta cells. PLoS One 2017; 12:e0175498.
23.
Natalicchio A, Marrano N, Biondi G, Spagnuolo R, Labarbuta R, Porreca I, Cignarelli A, Bugliani M, Marchetti P, Perrini S, Laviola L, and Giorgino F: The myokine irisin is released in response to saturated fatty acids and promotes pancreatic beta-cell survival and insulin secretion. Diabetes 2017; 66: 2849-2856.
24.
Zhang D, So WY, Wang Y, Wu SY, Cheng Q, and Leung PS: Insulinotropic effects of GPR120 agonists are altered in obese diabetic and obese non-diabetic states. Clin Sci (Lond) 2017; 131: 247-260.
25.
Li SYT, Cheng STW, Zhang D, and Leung PS: Identification and functional implications of sodium/myo-inositol cotransporter 1 in pancreatic beta-cells and type 2 diabetes. Diabetes 2017; 66: 1258-1271.
26.
Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, and Kim JB: Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes 2007; 56: 1534-1543.
27.
Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, and Fontes G: Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801: 289-298.
28.
Tiano JP, Delghingaro-Augusto V, Le May C, Liu S, Kaw MK, Khuder SS, Latour MG, Bhatt SA, Korach KS, Najjar SM, Prentki M, and Mauvais-Jarvis F: Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. J Clin Invest 2011; 121: 3331-3342.
29.
Okazaki Y, Eto K, Yamashita T, Okamoto M, Ohsugi M, Noda M, Terauchi Y, Ueki K, and Kadowaki T: Decreased insulin secretion and accumulation of triglyceride in beta cells overexpressing a dominant-negative form of AMP-activated protein kinase. Endocr J 2010; 57: 141-152.
30.
Kato T, Shimano H, Yamamoto T, Ishikawa M, Kumadaki S, Matsuzaka T, Nakagawa Y, Yahagi N, Nakakuki M, Hasty AH, Takeuchi Y, Kobayashi K, Takahashi A, Yatoh S, Suzuki H, Sone H, and Yamada N: Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 2008; 57: 2382-2392.
31.
Ha J, Daniel S, Broyles SS, and Kim KH: Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994; 269: 22162-22168.
32.
Jensen-Urstad AP, and Semenkovich CF: Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochim Biophys Acta 2012; 1821: 747-753.
33.
O’Neill HM, Holloway GP, and Steinberg GR: AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol Cell Endocrinol 2013; 366: 135-151.
34.
Thorens B: GLUT2, glucose sensing and glucose homeostasis. Diabetologia 2015; 58: 221-232.
35.
Thorens B, Weir GC, Leahy JL, Lodish HF, and Bonner-Weir S: Reduced expression of the liver/beta-cell glucose transporter isoform in glucose-insensitive pancreatic beta cells of diabetic rats. Proc Natl Acad U S A 1990; 87: 6492-6496.
36.
Matschinsky FM: Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45: 223-241.
37.
Fujimoto K, and Polonsky KS: Pdx1 and other factors that regulate pancreatic beta-cell survival. Diabetes Obes Metab 2009; 11 Suppl 4: 30-37.
38.
Tomita T: Apoptosis in pancreatic beta-islet cells in Type 2 diabetes. Bosn J Basic Med Sci 2016; 16: 162-179.
39.
Liu LM, Liu J, Gao YS, Yu XX, Xu G, and Huang Y: Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets. Brit J Pharmacol 2014; 171: 3246-3254.
40.
Zhou YP, Ling ZC, and Grill VE: Inhibitory effects of fatty acids on glucose-regulated B-cell function: association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolism. Metabolism 1996; 45: 981-986.
41.
Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, Irminger JC, Kergoat M, Portha B, Homo-Delarche F, and Donath MY: IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009; 106: 13998-14003.
42.
Mohamed J, Nazratun Nafizah AH, Zariyantey AH, and Budin SB: Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J 2016; 16:e132-141.
43.
Eguchi K, and Manabe I: Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab 2013; 15 Suppl 3: 152-158.
44.
Sorli CH, Zhang HJ, Armstrong MB, Rajotte RV, Maclouf J, and Robertson RP: Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U S A 1998; 95: 1788-1793.
45.
Burke SJ, Goff MR, Updegraff BL, Lu D, Brown PL, Minkin SC, Jr., Biggerstaff JP, Zhao L, Karlstad MD, and Collier JJ: Regulation of the CCL2 gene in pancreatic beta-cells by IL-1beta and glucocorticoids: role of MKP-1. PLoS One 2012; 7:e46986.
46.
Burke SJ, Lu D, Sparer TE, Masi T, Goff MR, Karlstad MD, and Collier JJ: NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription. Am J Physiol Endocrinol Metab 2014; 306:E131-149.
47.
Zhao J, Su Z, Qu C, and Dong Y: Effects of 12 Weeks Resistance Training on Serum Irisin in Older Male Adults. Front Physiol 2017; 8: 171.
48.
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, and Mantzoros CS: FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738.
49.
Huh JY, Mougios V, Kabasakalis A, Fatouros I, Siopi A, Douroudos II, Filippaios A, Panagiotou G, Park KH, and Mantzoros CS: Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocr Metab 2014; 99:E2154-E2161.
50.
Xin C, Liu J, Zhang J, Zhu D, Wang H, Xiong L, Lee Y, Ye J, Lian K, Xu C, Zhang L, Wang Q, Liu Y, and Tao L: Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obesity 2016; 40: 443-451.
51.
Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, Chen Q, Li YH, Wang JJ, Kang YM, and Zhu GQ: Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin Sci (Lond) 2015; 129: 839-850.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.